Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Additional capacity broadens Grace’s fine chemical capabilities for API production
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated
